News

NextGen Gene Therapy Vectors Conference 2022

Chameleon Founder Speaks at 2nd annual Gene Therapy Next Generation Vector Summit

March 10, 2022

Immunology and gene therapy CEO and scientist, Genine Winslow, presents innovative vector modifications at industry summit. Learn more about the conference and see the press release.

> Read More
Paul Fitzpatrick, Ph D

Chameleon Biosciences welcomes Paul Fitzpatrick, Ph.D.

February 22, 2022

We are very pleased to announce and welcome Paul Fitzpatrick to the Chameleon team as a Vice President of R&D. In this role, Paul will be responsible for leading Chameleon’s research team in the further development of our EVADER™ platform technology, developing our pipeline programs and facilitating collaborations.

> Read More
Genine Winslow, CEO & founder

Featured in BizWomen: Scientist Genine Winslow values having the right team

February 17, 2022

Before the COVID pandemic began, Genine Winslow and her team were already dealing in matters of illness and health. Learn about what inspired her to launch Chameleon Biosciences, the challenges that have arisen during the pandemic, and how she and her team are overcoming them and continuing to make progress toward life-changing gene therapies. Read the article—In Her Own Words:…

> Read More
Dr. Thomas Chalberg

Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, Joins as Newest Board Appointee

January 5, 2022

Thomas W. Chalberg, PhD, a scientist, entrepreneur, and executive in Silicon Valley has joined Chameleon’s Board of Directors. We look forward to working with Dr. Chalberg who has spent the past 15 years developing novel therapies and life-changing products.

> Read More

Press Releases

EVADER™ – stealth mode, next-generation AAV-based gene therapy vectors (published in BioPharma Dealmakers)

December 1, 2021

Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B and to programs that target retinal cells.

> Read More
Fall Private Company Showcase 2021-Solebury Trout, BMO

Chameleon Presents at Solebury Trout Fall Private Company Showcase 2021

November 5, 2021

Genine Winslow, CEO and Founder of Chameleon Biosciences, was invited to present at the 8th Annual Virtual Solebury Trout Fall Private Company Showcase. This selective, annual showcase highlights new and emerging biotechs. Ms. Winslow shared exciting preclinical data on Chameleon’s proprietary next generation AAV-based vectors which are designed to overcome the immune response related challenges of current AAV gene therapies. See the slides and more.

> Read More

Chameleon Biosciences at CureDuchenne’s National “FUTURES” Conference

October 1, 2021

Genine Winslow, CEO and Founder of Chameleon Biosciences will be participating in a panel discussion at the upcoming CureDuchenne’s National “FUTURES” Conference.

> Read More